Progression, remission, regression of chronic renal diseases
- PMID: 11377666
- DOI: 10.1016/S0140-6736(00)04728-0
Progression, remission, regression of chronic renal diseases
Abstract
The prevalence of chronic renal disease is increasing worldwide. Most chronic nephropathies lack a specific treatment and progress relentlessly to end-stage renal disease. However, research in animals and people has helped our understanding of the mechanisms of this progression and has indicated possible preventive methods. The notion of renoprotection is developing into a combined approach to renal diseases, the main measures being pharmacological control of blood pressure and reduction of proteinuria. Lowering of blood lipids, smoking cessation, and tight glucose control for diabetes also form part of the multimodal protocol for management of renal patients. With available treatments, dialysis can be postponed for many patients with chronic nephropathies, but the real goal has to be less dialysis-in other words remission of disease and regression of structural damage to the kidney. Experimental and clinical data lend support to the notion that less dialysis (and maybe none for some patients) is at least possible.
Comment in
-
Chronic renal disease.Lancet. 2001 Sep 22;358(9286):1012. doi: 10.1016/S0140-6736(01)06135-9. Lancet. 2001. PMID: 11586984 No abstract available.
-
Chronic renal disease.Lancet. 2001 Sep 22;358(9286):1012-3. doi: 10.1016/S0140-6736(01)06137-2. Lancet. 2001. PMID: 11586985 No abstract available.
Similar articles
-
Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?Minerva Med. 2004 Oct;95(5):395-409. Minerva Med. 2004. PMID: 15467515 Review.
-
The Remission Clinic approach to halt the progression of kidney disease.J Nephrol. 2011 May-Jun;24(3):274-81. doi: 10.5301/JN.2011.7763. J Nephrol. 2011. PMID: 21534237
-
Diabetic nephropathy--prevention and treatment.J Indian Med Assoc. 2002 Mar;100(3):158-60, 162-3. J Indian Med Assoc. 2002. PMID: 12408275 Review.
-
[Non-immunological therapy in nephropathies leading to chronic renal failure and in post-transplant chronic renal dysfunction].G Ital Nefrol. 2008 Nov-Dec;25 Suppl 44:53-63. G Ital Nefrol. 2008. PMID: 19048587 Review. Italian.
-
Prevention of progression and remission/regression strategies for chronic renal diseases: can we do better now than five years ago?Kidney Int Suppl. 2005 Sep;(98):S21-4. doi: 10.1111/j.1523-1755.2005.09804.x. Kidney Int Suppl. 2005. PMID: 16108966 Review.
Cited by
-
Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study.Springerplus. 2015 May 20;4:233. doi: 10.1186/s40064-015-1001-z. eCollection 2015. Springerplus. 2015. PMID: 26155438 Free PMC article.
-
Losartan and simvastatin inhibit platelet activation in hypertensive patients.J Thromb Thrombolysis. 2004 Dec;18(3):177-85. doi: 10.1007/s11239-005-0343-8. J Thromb Thrombolysis. 2004. PMID: 15815879 Clinical Trial.
-
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.J Am Soc Nephrol. 2008 May;19(5):999-1007. doi: 10.1681/ASN.2007060693. Epub 2008 Feb 13. J Am Soc Nephrol. 2008. PMID: 18272844 Free PMC article. Clinical Trial.
-
Proteinuria should be used as a surrogate in CKD.Nat Rev Nephrol. 2012 Mar 6;8(5):301-6. doi: 10.1038/nrneph.2012.42. Nat Rev Nephrol. 2012. PMID: 22391456 Review.
-
The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease.Rambam Maimonides Med J. 2015 Jul 30;6(3):e0029. doi: 10.5041/RMMJ.10214. Rambam Maimonides Med J. 2015. PMID: 26241225 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical